Real-World Study of Aumolertinib in Patients With Advanced EGFR T790M-Positive NSCLC
NCT07838532
Bronchial Neoplasms, Carcinoma, Bronchogenic
Nanjing, Jiangsu, China
View Trial DetailsNCT Number: NCT01167972
The main objective of the study is to determine the proportion of patients with M + mutation status among patients with Non Small Cell Lung Cancer adenocarcinoma.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Research Site, Abbeville, France
MSD
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: At baseline
Time frame: 12 months / At each visit
Time frame: 12 months / At each visit
Time frame: 12 months / At each visit
Looking for future studies?
Notify MeAstraZeneca
Industry
Observational Study on the Management of Patients With Non Small Cell Lung Cancer (NSCLC) Adenocarcinoma Tested for the Activating Mutation of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR TK)
Acronym: MUTACT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07838532
Bronchial Neoplasms, Carcinoma, Bronchogenic
Nanjing, Jiangsu, China
View Trial DetailsNCT05312840
Bronchial Neoplasms, Carcinoma, Bronchogenic
Quzhou, Zhejiang, China
View Trial DetailsNCT01350817
Bronchial Neoplasms, Carcinoma, Bronchogenic
Angers, France
View Trial DetailsNCT05858736
Adenocarcinoma, Adnexal Diseases
Darlinghurst, New South Wales, Australia
View Trial Details